Streptococcus Bovis Endocarditis and Its Association With Chronic Liver Disease: An Underestimated Risk Factor

Clin Infect Dis. 2004 May 15;38(10):1394-400. doi: 10.1086/392503. Epub 2004 Apr 28.

Abstract

Clinical and epidemiological characteristics of Streptococcus bovis endocarditis were prospectively studied among 199 patients with definite endocarditis. Thirty patients (15.1%) had S. bovis endocarditis. Compared with patients with non-S. bovis endocarditis, these 30 patients were older (mean age, 58.6+/-12.4 years vs. 46.0+/-17.0 years; P<.001) and had higher rates of bivalvular involvement (43.3% vs. 7.7%; P<.001), embolism (73.3% vs. 40.2%; P=.002), and diskitis (23.3% vs. 0.6% P<.001). In patients with S. bovis biotype I (S. bovis I) endocarditis, advanced liver disease was present in 56.7%, compared with 15.3% of patients with non-S. bovis endocarditis (P<.001), and colonic adenoma was present in 46.7%. The in-hospital mortality rate (16.7%) was correlated with delayed diagnosis and advanced liver diseases. In our city, S. bovis I endocarditis is frequently correlated with liver diseases; diskitis may be the first sign of the disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Chronic Disease
  • Colonic Neoplasms
  • Discitis / etiology*
  • Embolism / etiology
  • Endocarditis, Bacterial / complications*
  • Endocarditis, Bacterial / mortality
  • Female
  • Gastrointestinal Diseases / complications
  • Humans
  • Liver Diseases / complications*
  • Liver Diseases / epidemiology
  • Liver Function Tests
  • Male
  • Middle Aged
  • Risk Factors*
  • Streptococcal Infections / complications*
  • Streptococcal Infections / mortality
  • Streptococcus bovis* / drug effects

Substances

  • Anti-Bacterial Agents